- Neurotrophic keratitis (NK) is a rare degenerative corneal disease caused by damage to the trigeminal nerve, resulting in decreased corneal sensitivity and impaired healing. Treatment aims to restore corneal integrity, prevent ulceration, and preserve vision, using pharmacological and surgical interventions
- The demand for neurotrophic keratitis treatment is fueled by improved diagnosis rates, regulatory approvals of novel biologics like cenegermin, and expanded reimbursement frameworks in developed countries
- North America is expected to dominate the Neurotrophic keratitis treatment market with a share of 36.4%, attributed to the availability of FDA-approved therapies, high healthcare expenditure, and the strong presence of leading ophthalmic companies
- Asia-Pacific is expected to be the fastest growing region in the Neurotrophic keratitis treatment market during the forecast period due to increasing awareness, growing access to eye care, and rising incidence of diabetes and herpes infections, both of which are risk factors for NK.
- The recombinant human nerve growth factor (cenegermin) segment is expected to lead the market with a market share of 41.3% due to its proven efficacy in promoting corneal healing and the fact that it is the only FDA-approved drug specifically indicated for neurotrophic keratitis. Its targeted mechanism of action and increasing global adoption following regulatory approvals in multiple regions contribute to its dominant market position
